Influence, information overload, and information technology in health care

Adv Health Econ Health Serv Res. 2008:19:43-69.

Abstract

We investigate whether information technology (IT) can help physicians more efficiently acquire new knowledge in a clinical environment characterized by information overload. We combine analysis of data from a randomized trial with a theoretical model of the influence that IT has on the acquisition of new medical knowledge. Although the theoretical framework we develop is conventionally microeconomic, the model highlights the non-market and non-pecuniary influence activities that have been emphasized in the sociological literature on technology diffusion. We report three findings. First, empirical evidence and theoretical reasoning suggests that computer-based decision support will speed the diffusion of new medical knowledge when physicians are coping with information overload. Second, spillover effects will likely lead to "underinvestment" in this decision support technology. Third, alternative financing strategies common to new IT, such as the use of marketing dollars to pay for the decision support systems, may lead to undesirable outcomes if physician information overload is sufficiently severe and if there is significant ambiguity in how best to respond to the clinical issues identified by the computer. This is the first paper to analyze empirically and theoretically how computer-based decision support influences the acquisition of new knowledge by physicians.

Publication types

  • Review

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Cardiovascular Diseases / drug therapy
  • Clinical Competence*
  • Decision Support Systems, Clinical* / economics
  • Decision Support Systems, Clinical* / statistics & numerical data
  • Drug Industry / economics
  • Evidence-Based Medicine
  • Humans
  • Information Dissemination* / methods
  • Information Systems
  • Physicians / psychology*
  • Practice Patterns, Physicians'*
  • Randomized Controlled Trials as Topic
  • Reimbursement, Incentive

Substances

  • Angiotensin-Converting Enzyme Inhibitors